

Supplementary Table 3. Demographic data and baseline characteristics before propensity score matching

Characteristic	Cohort 1			Cohort 2		
	SGLT2i (n=21,713)	DPP-4i (n=104,224)	Standardized difference	SGLT2i (n=21,837)	SU (n=66,463)	Standardized difference
Age	51.8±12.0	58.0±12.6	50.2	51.8±12.0	58.0±13.1	49.2
Women	9,650 (44.4)	42,232 (40.5)	7.9	9,699 (44.4)	25,180 (37.9)	13.3
Index year						
2014	1,975 (9.1)	13,229 (12.7)	11.6	1,975 (9.0)	10,815 (16.3)	21.9
2015	7,902 (36.4)	44,694 (42.9)	13.3	7,902 (36.2)	31,391 (47.2)	22.5
2016	11,836 (54.5)	46,301 (44.4)	20.3	11,960 (54.8)	24,257 (36.5)	37.3
Comorbidities						
Cardiovascular disease	4,442 (20.5)	23,884 (22.9)	6.0	4,465 (20.4)	12,220 (18.4)	5.2
Myocardial infarction	432 (2.0)	2,190 (2.1)	0.8	429 (2.0)	1,013 (1.5)	3.4
PCI with stent	276 (1.3)	1,008 (1.0)	2.9	276 (1.3)	321 (0.5)	8.4
Unstable angina	658 (3.0)	3,244 (3.1)	0.5	658 (3.0)	1,489 (2.2)	4.8
Angina pectoris	2,509 (11.6)	12,151 (11.7)	0.3	2,524 (11.6)	5,708 (8.6)	9.9
Heart failure	1,033 (4.8)	4,945 (4.7)	0.1	1,032 (4.7)	2,372 (3.6)	5.8
Atrial fibrillation	389 (1.8)	2,290 (2.2)	2.9	384 (1.8)	1,058 (1.6)	1.3
Stroke	1,452 (6.7)	10,301 (9.9)	11.6	1,465 (6.7)	5,582 (8.4)	6.4
Peripheral artery disease	13 (0.1)	74 (0.1)	0.4	13 (0.1)	43 (0.1)	0.2
Chronic kidney disease	165 (0.8)	1,131 (1.1)	3.4	163 (0.7)	534 (0.8)	0.7
Diabetic neuropathy	1,975 (9.1)	11,386 (10.9)	6.1	1,996 (9.1)	6,255 (9.4)	0.9
Diabetic retinopathy	2,886 (13.3)	15,310 (14.7)	4.0	2,907 (13.3)	7,272 (10.9)	7.3
Diabetic nephropathy	2,738 (12.6)	10,951 (10.5)	6.6	2,773 (12.7)	3,566 (5.4)	25.8
Severe hypoglycemia	241 (1.1)	1,221 (1.2)	0.6	244 (1.1)	830 (1.2)	1.2
Keto-/lactate acidosis	78 (0.4)	344 (0)	0.5	78 (0.4)	244 (0.4)	0.2
Cancer	1,749 (8.1)	10,378 (10.0)	6.6	1,761 (8.1)	5,255 (7.9)	0.6
Frailty (yes)	364 (1.7)	3,326 (3.2)	9.8	364 (1.7)	3,304 (5.0)	18.5
Drugs						
Low dose acetylic salicylic acid	3,764 (17.3)	21,677 (20.8)	8.8	3,770 (17.3)	12,052 (18.1)	2.3
Statin therapy	13,303 (61.3)	57,228 (54.9)	12.9	13,387 (61.3)	25,761 (38.8)	46.3
ACE inhibitors	461 (2.1)	2,356 (2.3)	0.9	462 (2.1)	1,358 (2.0)	0.5
ARB	9,247 (42.6)	41,366 (39.7)	5.9	9,291 (42.5)	23,847 (35.9)	13.7
Dihydropyridines	3,348 (15.4)	20,757 (19.9)	11.8	3,367 (15.4)	14,790 (22.3)	17.5
Low ceiling diuretics	1,402 (6.5)	7,445 (7.1)	2.7	1,404 (6.4)	5,205 (7.8)	5.5
Beta blockers	3,212 (14.8)	15,454 (14.8)	0.1	3,215 (14.7)	8,731 (13.1)	4.6
Non-hydropyridines	477 (2.2)	2,500 (2.4)	1.3	477 (2.2)	1,055 (1.6)	4.4
High ceiling diuretics	678 (3.1)	4,726 (4.5)	7.4	674 (3.1)	2,613 (3.9)	4.6
Aldosterone antagonists	328 (1.5)	2,098 (2.0)	3.8	329 (1.5)	1,103 (1.7)	1.2
Warfarin	126 (0.6)	926 (0.9)	3.6	125 (0.6)	410 (0.6)	0.6
Receptor P2Y12 antagonists	1,223 (5.6)	7,829 (7.5)	7.6	1,228 (5.6)	3,415 (5.1)	2.2

Values are presented as mean ± standard deviation or number (%). Frailty was defined by at least one hospital admission of ≥3 consecutive days during preceding year before the index date.

SGLT2i, sodium glucose cotransporter 2 inhibitor; DPP-4i, dipeptidyl peptidase-4 inhibitor; SU, sulfonylurea; PCI, percutaneous coronary intervention; ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker.